BioSenic fait le point sur ses activités du premier trimestre 2024
May 24, 2024 11:00 ET
|
BioSenic
COMMUNIQUE DE PRESSE – INFORMATION REGLEMENTEE Mont-Saint-Guibert, Belgique, le 24 mai 2024 à 17h00 CEST – BIOSENIC (Euronext Bruxelles et Paris : BIOS), la société en phase clinique spécialisée...
BioSenic provides First Quarter 2024 Business Update
May 24, 2024 11:00 ET
|
BioSenic
PRESS RELEASE – REGULATED INFORMATION Mont-Saint-Guibert, Belgium, May 24, 2024, 17.00am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious...
Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
May 24, 2024 10:00 ET
|
Apellis Pharmaceuticals, Inc.
Rapid reduction in disease activity seen at 12 weeks was sustained at one year 55% of patients showed zero C3c staining intensity, indicating that C3c deposits were clearedHighlighted as late-breaking...
Edible Garden Completes Phase Two of Packhouse Buildout at Company’s Flagship Belvidere NJ Facility
May 24, 2024 09:15 ET
|
Edible Garden AG Incorporated
Packhouse adds Processing and Warehousing Capabilities to Facility; Expected to Expand Company’s Capacity State-of-the-Art GreenThumb Technology to be Integrated at Facility; Expected to Increase...
Scilex Holding Company Sends Letter to U.S. House of Representatives on Illegal Market Manipulation of the Common Stock of Scilex Holding Company
May 24, 2024 09:00 ET
|
Scilex Holding Company
PALO ALTO, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and...
BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024
May 24, 2024 08:00 ET
|
BriaCell Therapeutics Corp.
83% intracranial objective response rate (iORR) with Bria-IMT™ in heavily pretreated advanced breast cancer patients with CNS metastasesMedian progression free survival (PFS) of 4.1 months in ADC...
IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024
May 24, 2024 08:00 ET
|
IN8bio, Inc
IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
May 24, 2024 08:00 ET
|
CG Oncology Inc.
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab
2-Day Online Process Validation Guidance Requirements Course: July 25-26, 2024 (FDA and EU Annex 15: Qualifications and Validation)
May 24, 2024 07:28 ET
|
Research and Markets
Dublin, May 24, 2024 (GLOBE NEWSWIRE) -- The "Process Validation Guidance Requirements course (FDA and EU Annex 15: Qualifications and Validation) Course" training has been added to ...
Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress
May 24, 2024 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, May 24, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop...